Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC

Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we would like to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This is the joint webinar between IASLC and JLCS (Japan Lung Cancer Society, https://www.haigan.gr.jp/). This webinar will consist of a 20-minute presentation from the keynote speaker, Dr. Enriqueta Felip, given in English, followed by a 25-minute panel discussion conducted in Japanese with 15-minutes at the end for Q&A.